Gilbert Hin-Lung Tang, MD, MSc, MBA, FACC

Surgical and Academic Director, Structural Heart Program
Mount Sinai Health System

Printed as of 7/1/2025

Disclosures

Personal Commercial (13)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Abbott Structural Heart	Other - Advisory board member, Anatomic eligibility committee member and Publications committee of the TRILUMINATE trial	Significant (>= \$5,000)	Invasive CV Angio and Interventions Valvular Heart Disease
Abbott Structural Heart	Consultant Fees/Honoraria	Significant (>= \$5,000)	Invasive CV Angio and Interventions Valvular Heart Disease
Abbott Structural Heart	Speaker's Bureau	Significant (>= \$5,000)	Invasive CV Angio and Interventions Valvular Heart Disease
Anteris	Speaker's Bureau	Modest (< \$5,000)	Valvular Heart Disease
Anteris	Consultant Fees/Honoraria	Modest (< \$5,000)	Valvular Heart Disease
Boston Scientific	Consultant Fees/Honoraria	Modest (< \$5,000)	Invasive CV Angio and Interventions Valvular Heart Disease
Edwards Lifesciences	Consultant Fees/Honoraria	Modest (< \$5,000)	Valvular Heart Disease
Medtronic	Other - Advisory board member, TAVR publications committee member, Screening committee member of the APOLLO trial and Steering committee member of the IMPACT-MR trial	Significant (>= \$5,000)	Invasive CV Angio and Interventions Noninvasive Imaging Valvular Heart Disease
Medtronic	Speaker's Bureau	Significant (>= \$5,000)	Cardiothoracic Surgery Invasive CV Angio and Interventions Valvular Heart Disease
Medtronic	Consultant Fees/Honoraria	Significant (>= \$5,000)	Valvular Heart Disease
Peija Medical	Consultant Fees/Honoraria	Modest (< \$5,000)	Invasive CV Angio and Interventions Valvular Heart Disease
Shenqi Medical Technology	Consultant Fees/Honoraria	Significant (>= \$5,000)	Invasive CV Angio and Interventions Valvular Heart Disease
Shockwave Medical	Consultant Fees/Honoraria	Modest (< \$5,000)	Invasive CV Angio and Interventions Valvular Heart Disease

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/3/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/Certified Education Attestation Agreement agreement

URL for full agreement: http://disclosures.acc.org/Public/Definition/Confidentiality Disclosure and Assignment Agreement agreement

Embargo | Signed on 10/3/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 5/22/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.